QM107, a novel CD148 (RTP Type J) activating peptide therapy for treating neovascular age‐related macular degeneration
We have developed a CD148 activating peptide which shows promise in inhibiting angiogenesis in models of neovascular age-related macular degeneration. This treatment could either represent an alternative or augment existing therapies, and owing to its distinct mode of action be used in patients who do not respond to existing treatments.
Authors
- Matteo Rizzi (ORCID: https://orcid.org/0000-0003-4922-397X)
- Giulia De Rossi (ORCID: https://orcid.org/0000-0001-6163-4590)
- Samantha Arokiasamy
- Iván O. Rosas (ORCID: https://orcid.org/0000-0003-4622-618X)
- Faheem Shaik
- Konstantin Tsoyi (ORCID: https://orcid.org/0000-0001-5843-5427)
- James Bainbridge (ORCID: https://orcid.org/0000-0003-1318-8201)
- Enrico Cristante (ORCID: https://orcid.org/0000-0002-5454-1553)
- Michaela J. M. Balderstone
- Tanya W. Moseley (ORCID: https://orcid.org/0000-0002-2018-8253)
- James R. Whiteford (ORCID: https://orcid.org/0000-0002-8967-7389)
- Akshay Madoo
Institutions
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- Queen Mary University of London (GB)
- Baylor College of Medicine (US)
- William Harvey Research Institute (GB)
- Moorfields Eye Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-10-20
- DOI
- https://doi.org/10.1111/bph.17362
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Queen Mary University of London
- Macular Society
- William Harvey Research Foundation
- Barts Charity
- National Institute for Health and Care Research
- Arthritis Research UK
- Diabetes UK
- Dunhill Medical Trust
- Fight for Sight UK
- Moorfields Eye Charity